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Background: Lipid-reduction pharmacotherapy is often employed to reduce morbidity and mortality risk for
patients with dyslipidemia or established cardiovascular disease. Associations between socioeconomic factors and
the prescribing and use of lipid-lowering agents have been reported in several developed countries.
Methods: We evaluated the association of census tract-level neighborhood household income (nINC) and lipid-
lowering medications received during hospitalization or at discharge among 3,546 (5,335 weighted) myocardial
infarction (MI) events in the United States (US) Atherosclerosis Risk In Communities (ARIC) surveillance study
(1999–2002). Models included neighborhood household income, race, gender, age, study community, year of MI,
hospital type (teaching vs. nonteaching), current or past history of hypertension, diabetes or heart failure, and
presence of cardiac pain.
Results: About fifty-nine percent of patients received lipid-lowering pharmacotherapy during hospitalization or at
discharge. Low nINC was associated with a lower likelihood (prevalence ratio 0.89, 95% confidence interval: 0.79,
1.01) of receiving lipid-lowering pharmacotherapy compared to high neighborhood household income, and no
significant change in this association resulted when adjusted for the above-mentioned covariates.
Conclusion: Patient’s socioeconomic status appeared to influence whether they were prescribed a lipid-lowering
pharmacotherapy after hospitalization for myocardial infarction in the US ARIC surveillance study (1999–2002).
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Lipid reduction can significantly improve cardiovascular
risk and lower morbidity and mortality following myo-
cardial infarction (MI). Pharmacotherapy, along with
lifestyle changes, plays an essential role in improving
lipid profiles. Statins, arguably the most efficacious of
the lipid-lowering drug classes, are often first-line
therapy for the dyslipidemias and for decreasing cardio-
vascular risk. However, investigators worldwide have
reported that socioeconomic factors often influence the
prescribing and use of statins and other lipid-lowering
agents. In 2007 Ward et. al. published data from four
primary-care trusts in Northwest England that indicated* Correspondence: kathy_rose@sra.com
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reproduction in any medium, provided the orethnic inequities in statin prescribing rates [1]. A Danish
study published in 2005 reported that among men with
cardiovascular disease, statin use was higher in those
with the highest socioeconomic status (SES) and lower
among retired men in old-age pensioners compared to
basic-level workers [2]. An Australian study published in
2004 found that statins were prescribed for males when
indicated more often to those with higher SES and were
prescribed for females at higher rates at lower levels of
risk [3]. In 2006 a report describing significant dispar-
ities in the use of lipid-lowering agents in the United
States (US) was published [4]; however, such studies
investigating SES and the use of lipid-lowering medica-
tions in the US are rare. Our previous work described
differential receipt of aspirin, beta-blockers, and angio-
tensin converting enzyme inhibitors by neighborhood
SES [5]. This brief report discusses our subsequental Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Receipt of lipid-lowering pharmacotherapy among
Atherosclerosis Risk in Community (ARIC) surveillance patients
(1999–2002). Model 1: Neighborhood income (nINC), race, gender,
age, study community, year of myocardial infarction (MI). Model 2:
Model 1 plus hospital type (teaching vs. nonteaching), current or
past history of hypertension, diabetes or heart failure, and presence
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hood SES and lipid-lowering pharmacotherapy.
Methods
We evaluated the association between tertiles (low,
medium, and high) of census tract-level neighborhood
household income (nINC) and lipid-lowering medications
received during hospitalization or at discharge among
3,546 (5,335 weighted) MI events in the US Atheroscler-
osis Risk In Communities (ARIC) surveillance study
(1999–2002). The ARIC study’s community-based surveil-
lance of coronary heart disease has been ongoing since
1987 and is designed to capture MI and fatal coronary
heart disease events in four US communities [Jackson,Table 1 Receipt of lipid-lowering pharmacotherapy
among Atherosclerosis Risk in Community (ARIC)
surveillance patients (1999–2002): results from regression
models for selected variables
Variable Prevalence ratio 95% CI
Model 1
nINC
Low nINC 0.89 0.79, 1.01
Medium nINC 0.98 0.91, 1.07
High nINC 1.00 ref
Gender
Female 0.91 0.84, 0.98
Male 1.00 ref
Race




Low nINC 0.91 0.81, 1.03
Medium nINC 1.00 0.92,1.08
High nINC 1.00 ref
Gender
Female 0.92 0.85, 1.00
Male 1.00 ref
Race
Black 0.90 0.79, 1.02
White 1.00 ref
Hospital type
Teaching 0.87 0.79, 0.96
Non-teaching 1.00 ref
Medical history
Hypertension 0.99 0.92, 1.06
Diabetes 1.05 0.97, 1.14
Heart failure 0.72 0.65, 0.79
of cardiac pain.Mississippi (MS); Forsyth County, North Carolina (NC);
Washington County, Maryland (MD); and Minneapolis,
Minnesota (MN)]). While it comprises the same commu-
nities from which ARIC cohort members were recruited,
ARIC community surveillance does not include in-person
physical exams, annual follow-up, or any contact with
ARIC cohort participants (unless they happen to be sam-
pled as a surveillance case). ARIC community-surveillance
staff ascertained coronary heart disease-related hospital
discharges and deaths and abstracted data related to the
event of interest. Institutional Review Board (IRB) ap-
provals were obtained by each participating ARIC study
center (the Universities of NC, MS, MN, and John
Hopkins University) and the coordinating center (Univer-
sity of NC), and the research was conducted in accordance
with the principles described in the Declaration of
Helsinki. Data for this study were abstracted from medical
records and strict data confidentiality was maintained.
Further details regarding ARIC’s methods for data collec-
tion are provided elsewhere [6]. For our analyses, we
weighted the hospitalized MI cases based on the probabil-
ity sampling of selected International Classification of
Disease codes [6] in order to estimate the eligible popula-
tion of cases that would have been studied had the prob-
ability sampling not been employed.
We estimated prevalence ratios and 95% confidence
intervals for receipt of lipid-lowering medication post-
MI using weighted Poisson regression, and we used
generalized estimation equations (PROC GENMOD,
SAS Institute) to account for the clustering of MI events
within census tracts and within patients, as incident and
recurrent MI events were considered together based
upon our previous analyses [7,8]. Model 1 included
nINC, race, gender, age, study community and year of
MI. Model 2 included the same parameters as well as
hospital type (teaching vs. nonteaching), current or past
history of hypertension, diabetes or heart failure, and
presence of cardiac pain. Additionally, we examined
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lipid-lowering therapy relationship: race, gender, age,
study community and year of MI. Models utilizing tertiles
defined by overall nINC cut-points were evaluated, as in-
terpretations of our earlier work in this population did not
change based on the delineation (community-specific,
race-specific, and overall cut-points) of nINC tertiles [9].
Results and discussion
The MI cases were distributed across the four ARIC
study communities as follows: 25.7% in MS, 36.7% in
NC, 15.9% in MD, and 21.7% in MN. The MI patients
were 34.5% female, 25.3% black, and had an average age
of 60.2 years. The mean nINC was approximately $42,700.
Overall, 58.5% of patients received lipid-lowering pharma-
cotherapy during hospitalization or at discharge. In
models adjusted for race, gender, age, study community
and year of MI, there was no significant effect modifica-
tion of the nINC- lipid-lowering therapy relationship by
race, gender, age, study community or year of MI as indi-
cated in these data. Results of models utilizing overall cut-
points are reported in Table 1 and Figure 1. In Model 1,
low nINC was associated with a lower likelihood (preva-
lence ratio 0.89, 95% confidence interval: 0.79, 1.01) of re-
ceiving lipid-lowering pharmacotherapy compared to high
nINC. This relationship did not change substantially when
the additional parameters (hospital type, current or past
history of hypertension, diabetes or heart failure, and pres-
ence of cardiac pain) were included (Model 2). Although
lipid-lowering pharmacotherapy remains a central compo-
nent of cardiovascular-risk-profile optimization, several
investigators worldwide have reported significant associa-
tions among socioeconomic parameters and statin pre-
scribing. Our investigation suggests that prescribing of
lipid-lowering pharmacotherapies may be influenced by
neighborhood SES in the US ARIC study population
(1999–2002).
Conclusions
Our results demonstrate that a patient’s SES may influ-
ence whether they were prescribed a lipid-lowering
pharmacotherapy after hospitalization for MI in the US
ARIC surveillance study (1999–2002). This observation
should be noted by clinicians, patients, and policy
makers. Efforts to decrease or eliminate the influence of
socioeconomic factors on the prescribing of pharmaco-
therapy should be implemented.
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